Latanoprost/trabodenoson

Drug Profile

Latanoprost/trabodenoson

Alternative Names: INO 8875/trabodenoson; PJ 875/trabodenoson; Trabodenoson/latanoprost

Latest Information Update: 07 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inotek Pharmaceuticals
  • Class Prostaglandins; Small molecules
  • Mechanism of Action Adenosine A1 receptor agonists; Gelatinase stimulants; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glaucoma; Ocular hypertension

Most Recent Events

  • 31 Jul 2017 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
  • 31 Jul 2017 Discontinued - Phase-II for Ocular hypertension in USA (Ophthalmic)
  • 07 Jul 2017 Top-line efficacy and adverse events data from a phase II trial in Glaucoma and Ocular hypertension released by Inotek Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top